April 10, 2017 - Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide

Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise’s ImSus® Technology Platform for the development of an injectable, controlled-release formulation of a peptide therapeutic.

Under the terms of the agreement, Alrise will conduct feasibility and scale-up studies with Ferring. Upon completion of the development work, Ferring will have the right to exercise its option and enter into a definitive agreement with Alrise to further develop and manufacture the formulation.

“Ferring aims to harness innovative technology platforms, such as Alrise’s microparticle-technology platform, in order to provide new, controlled-release formulations of peptides and proteins for our patients,” said Alan S. Harris, Senior Vice President, R&D Executive Office, Ferring Pharmaceuticals. “Controlled, long-duration release treatments can maximise efficiency, help improve compliance to treatment, and make life simpler for our patients.”

“Alrise is committed to delivering solutions that enhance the performance of drug products in development,” said Volker Rindler, Head of Business Development and Co-Founder, Alrise Biosystems. “Together with Ferring we aim to develop a new depot formulation that, once injected, releases the drug in a controlled way and thereby ensures an effective drug level over several months.”

...

ALRISE Will Be Attending CPhI in Frankfurt (October 24-26) and BioEurope in Berlin (November 6-8)

If you would like to meet us there, please contact Volker Rindler (rindler@alrise.de).

ALRISE Biosystems GmbH
Robert-Roessle-Straße 10
Otto-Warburg-Haus
13125 Berlin, Germany
Phone +49 30.94 89 24 83
Fax +49 30.94 89 24 82
info@alrise.de